tetano
Editor, Senior Moderator
PLoS One. 2014 Jun 17;9(6):e99322. doi: 10.1371/journal.pone.0099322. eCollection 2014.
Response of Mice and Ferrets to a Monovalent Influenza A (H7N9) Split Vaccine.
Duan Y1, Gu H1, Chen R2, Zhao Z1, Zhang L1, Xing L1, Lai C1, Zhang P3, Li Z3, Zhang K3, Wang Z3, Zhang S3, Wang X1, Yang P4.
Author information
Abstract
In early spring 2013, the emergence of the influenza A (H7N9) virus in humans in Eastern China raised concerns of a new influenza pandemic. Development of a safe and effective H7N9 influenza vaccine is urgently needed. To this end, we first synthesized the hemagglutinin (HA) and neuraminidase (NA) genes of the influenza A (H7N9) virus A/AnHui/1/2013. Using reverse genetics, we rescued a reassortant virus (H7N9/PR8) that contained the HA and NA genes from wild-type H7N9 and six genes encoding internal proteins from the A/Puerto Rico/8/34 (PR8) virus. Next, the pathogenicity of the reassortant virus was evaluated both in vivo and in vitro. We found that the virus was non-pathogenic in mice and was stable after serial passaging in eggs. Furthermore, we found that a monovalent influenza A (H7N9) split vaccine prepared from the virus was immunogenic in mice and ferrets. When given intramuscularly, the vaccine (two doses of at least 15-?g) completely protected mice from normally lethal wild-type H7N9 virus challenge. In summary, our H7N9 vaccine, developed over a short time, is a potential candidate for further clinical evaluation and human use.
PMID:
24937303
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/24937303
Response of Mice and Ferrets to a Monovalent Influenza A (H7N9) Split Vaccine.
Duan Y1, Gu H1, Chen R2, Zhao Z1, Zhang L1, Xing L1, Lai C1, Zhang P3, Li Z3, Zhang K3, Wang Z3, Zhang S3, Wang X1, Yang P4.
Author information
Abstract
In early spring 2013, the emergence of the influenza A (H7N9) virus in humans in Eastern China raised concerns of a new influenza pandemic. Development of a safe and effective H7N9 influenza vaccine is urgently needed. To this end, we first synthesized the hemagglutinin (HA) and neuraminidase (NA) genes of the influenza A (H7N9) virus A/AnHui/1/2013. Using reverse genetics, we rescued a reassortant virus (H7N9/PR8) that contained the HA and NA genes from wild-type H7N9 and six genes encoding internal proteins from the A/Puerto Rico/8/34 (PR8) virus. Next, the pathogenicity of the reassortant virus was evaluated both in vivo and in vitro. We found that the virus was non-pathogenic in mice and was stable after serial passaging in eggs. Furthermore, we found that a monovalent influenza A (H7N9) split vaccine prepared from the virus was immunogenic in mice and ferrets. When given intramuscularly, the vaccine (two doses of at least 15-?g) completely protected mice from normally lethal wild-type H7N9 virus challenge. In summary, our H7N9 vaccine, developed over a short time, is a potential candidate for further clinical evaluation and human use.
PMID:
24937303
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/24937303